Resource Overview
Glucagon-like peptide-1 (GLP-1) receptor agonists, once diabetes treatments, have exploded into popular culture as a powerful weight-loss medicine. With oral formulations now reaching the market, GLP-1s may turn out to be the drug class of a decade. Due to its short half-life, researchers have developed GLP-1 analogs with longer half-lives for clinical use.
Analysis of GLP-1 analogues can often be challenging due to poor ionization and fragmentation due to the inherent large peptide structure. Therefore, a highly sensitive method is essential for the quantification of GLP-1 analogs.
Key Takeaways:
- Read about the primary actions of GLP-1: (enhances insulin secretion, reduces glucagon, slows gastric emptying, and reduces appetite)
- View methods for structure function analysis, measuring binding kinetics and receptor affinity of three leading GLP-1 analogs: Victoza® (liraglutide), Trulicity® (dulaglutide), and Ozempic® (semaglutide)
- Learn about the many advantages of using the Octet® BLI system to assess the biophysical interaction of GLP-1 and its analogs binding to the receptor
- Explore how structural modifications such as amino acid substitutions and fatty acid attachments can significantly enhance the stability and efficacy of GLP-1 analogs (with one analog showing significantly higher affinity than its competitors)
Resource Details:
- Document Type: Application Note
- Audience: Therapeutic researchers working to improve treatment of type-2 diabetes and related conditions
- Page Count: 6
- Read Time: 10 minutes